Hereditary Prostate Cancer Panel

Casandra

Casandra Test Code MC51221Version 1 (DRAFT)

Performing Lab

Lab Mayo Clinic LabLab Test ID PRS8PCPT Code 81432

Hereditary Prostate Cancer Panel

Clinical Use

Use

This test is used for evaluating patients with a personal or family history suggestive of a hereditary prostate cancer syndrome. It aids in establishing a diagnosis of a hereditary prostate cancer syndrome, allowing for targeted cancer surveillance based on associated risks. It also identifies genetic variants associated with an increased risk for prostate cancer, enabling predictive testing and appropriate screening of at-risk family members. The test is essential for determining therapeutic eligibility for poly adenosine diphosphate-ribose polymerase (PARP) inhibitors based on certain gene alterations, such as BRCA1 and BRCA2.

Special Instructions

Testing minors for adult-onset predisposition syndromes is discouraged by the American Academy of Pediatrics, the American College of Medical Genetics and Genomics, and the National Society of Genetic Counselors. Specimens are preferred to be received within 4 days of collection to ensure DNA integrity.

Limitations

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results can occur. Certain gene regions may not be effectively evaluated due to technical limitations such as homology, high guanine-cytosine (GC) content, and repetitive sequences. The test is not designed to detect low levels of mosaicism or to differentiate between somatic and germline variants. Additionally, results may be inaccurate in patients with an allogeneic hematopoietic stem cell transplant or a recent blood transfusion.

Test Details

New York Approved